Obstruction of Malignancy: Percutaneous Renal vs Endoscopic Stent
Cancer, Urinary Obstruction, Malignancy
About this trial
This is an interventional treatment trial for Cancer focused on measuring urinary issues, urinary obstruction, cancer
Eligibility Criteria
Inclusion Criteria Patients must have unilateral or bilateral hydronephrosis secondary to extrinsic compression by malignancy on cross sectional imaging. Age ≥18 years. Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria Anticoagulation that cannot be safely reversed in the peri-procedural time period. History of severe allergy to contrast media. Prior stent or nephrostomy in previous 6 months. Urethral or ureteric stricture disease. Lower urinary tract structural abnormalities or urinary diversion precluding retrograde ureteral stent placement. On blood pressure support or clinically unstable. Pregnant women are excluded from this study because the radiation from either procedure is known to have the potential for teratogenic or abortifacient effects. Previous renal transplant. Dialysis
Sites / Locations
- The University of ChicagoRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
Group A (Ureteral Stenting)
Group B (Percutaneous Nephrostomy)
Group A: Participants in this group will receive a standard of care ureteral stenting performed by a urologist.
Participants in this group will receive a standard of care percutaneous nephrostomy tube placement performed by an interventional radiologist.